[go: up one dir, main page]

PL3358355T3 - Zastosowanie surowiczych peroksyredoksyn dwucysteinowych (2-Cys-PRDX) jako biomarkerów przewlekłej choroby nerek (PChN, ang. CKD) takiej jak toczniowe zapalenie nerek (LN), nefropatia IgA (IgAN) i autosomalna dominująca wielotorbielowatość nerek (ADPKD) użytecznych do diagnozowania tych chorób i sposoby różnicowania tych chorób - Google Patents

Zastosowanie surowiczych peroksyredoksyn dwucysteinowych (2-Cys-PRDX) jako biomarkerów przewlekłej choroby nerek (PChN, ang. CKD) takiej jak toczniowe zapalenie nerek (LN), nefropatia IgA (IgAN) i autosomalna dominująca wielotorbielowatość nerek (ADPKD) użytecznych do diagnozowania tych chorób i sposoby różnicowania tych chorób

Info

Publication number
PL3358355T3
PL3358355T3 PL17461508.8T PL17461508T PL3358355T3 PL 3358355 T3 PL3358355 T3 PL 3358355T3 PL 17461508 T PL17461508 T PL 17461508T PL 3358355 T3 PL3358355 T3 PL 3358355T3
Authority
PL
Poland
Prior art keywords
diseases
prdx
adpkd
igan
ckd
Prior art date
Application number
PL17461508.8T
Other languages
English (en)
Inventor
Krzysztof MUCHA
Radosław Zagożdżon
Bartosz FORONCEWICZ
Leszek PĄCZEK
Natalia KRATA
Kamila GALA
Original Assignee
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny filed Critical Warszawski Uniwersytet Medyczny
Publication of PL3358355T3 publication Critical patent/PL3358355T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • G01N2333/908Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL17461508.8T 2017-02-04 2017-02-04 Zastosowanie surowiczych peroksyredoksyn dwucysteinowych (2-Cys-PRDX) jako biomarkerów przewlekłej choroby nerek (PChN, ang. CKD) takiej jak toczniowe zapalenie nerek (LN), nefropatia IgA (IgAN) i autosomalna dominująca wielotorbielowatość nerek (ADPKD) użytecznych do diagnozowania tych chorób i sposoby różnicowania tych chorób PL3358355T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17461508.8A EP3358355B1 (en) 2017-02-04 2017-02-04 Use of serum 2-cysteine peroxiredoxins (2-cys-prdx) as biomarkers of chronic kidney diseases (ckd) such as lupus nephritis (ln), iga nephropathy (igan) and autosomal-dominant polycystic kidney disease (adpkd) useful for diagnosing, these diseases and method of differentiation of these diseases

Publications (1)

Publication Number Publication Date
PL3358355T3 true PL3358355T3 (pl) 2024-04-08

Family

ID=57984871

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17461508.8T PL3358355T3 (pl) 2017-02-04 2017-02-04 Zastosowanie surowiczych peroksyredoksyn dwucysteinowych (2-Cys-PRDX) jako biomarkerów przewlekłej choroby nerek (PChN, ang. CKD) takiej jak toczniowe zapalenie nerek (LN), nefropatia IgA (IgAN) i autosomalna dominująca wielotorbielowatość nerek (ADPKD) użytecznych do diagnozowania tych chorób i sposoby różnicowania tych chorób

Country Status (7)

Country Link
US (1) US20200064344A1 (pl)
EP (1) EP3358355B1 (pl)
AU (1) AU2018215249A1 (pl)
CA (1) CA3052545A1 (pl)
IL (1) IL268477A (pl)
PL (1) PL3358355T3 (pl)
WO (1) WO2018141975A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102403211B1 (ko) * 2020-08-21 2022-05-27 중앙대학교 산학협력단 퍼옥시레독신 4를 이용한 포유동물의 산자수 예측용 조성물
CN117491636A (zh) * 2023-11-21 2024-02-02 郑州大学 一种用于肺癌诊断的生物标志物及其应用
CN118962136B (zh) * 2024-10-17 2024-12-13 中南大学湘雅二医院 Prdx2作为生物标志物在急性肾损伤辅助诊断和预后预测中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1360965A4 (en) 2001-02-16 2009-07-29 Asubio Pharma Co Ltd METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH A DECREASE OF THE EXPOSURE OF THE AOP-1 GENE OR AOP-1 AND MEANS FOR THE TREATMENT OF THE DISEASES
WO2005116082A1 (en) 2004-05-27 2005-12-08 Industry-Academic Cooperation Foundation Gyeong Sang National University 2-cysteine peroxiredoxin complex exhibiting function acting as molecular chaperone and uses thereof
WO2009151511A1 (en) 2008-04-29 2009-12-17 Therasis, Inc. Systems and methods for identifying combinations of compounds of therapeutic interest
KR100928403B1 (ko) 2008-10-01 2009-11-26 경북대학교 산학협력단 티지비엠 신증의 진단용 조성물 및 키트
WO2010099477A2 (en) 2009-02-27 2010-09-02 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
WO2011081229A1 (ko) 2009-12-29 2011-07-07 이화여자대학교 산학협력단 혈관신생 억제용 약제학적 조성물
US20130040833A1 (en) 2010-05-12 2013-02-14 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
US20130210667A1 (en) 2010-09-10 2013-08-15 The Ohio State University Biomarkers for Predicting Kidney and Glomerular Pathologies
EP3151012B1 (en) * 2010-09-21 2018-03-21 Proteomics International Pty Ltd Biomarkers associated with diabetic nephropathy
US20140038203A1 (en) * 2012-07-09 2014-02-06 Musc Foundation For Research Development Methods for detecting or predicting kidney disease
US20140221325A1 (en) * 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Glomerulonephritis biomarkers
HK1248804A1 (zh) 2015-03-30 2018-10-19 Hycor生物医学有限责任公司 用於执行自身免疫性疾病和感染性疾病的诊断性测定的自动化的免疫分析仪系统

Also Published As

Publication number Publication date
AU2018215249A1 (en) 2019-08-22
EP3358355B1 (en) 2023-10-11
WO2018141975A1 (en) 2018-08-09
US20200064344A1 (en) 2020-02-27
EP3358355A1 (en) 2018-08-08
IL268477A (en) 2019-09-26
CA3052545A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
EP3734395A4 (en) METHOD OF SWITCHING THE OPERATING MODE OF A CARDAN SUSPENSION AND CONTROL AND IMAGE STABILITY ENHANCEMENT DEVICE
EP3221835A4 (en) Model-based prediction of an optimal convenience metric for authorizing transactions
EP3161481A4 (en) System for assessing global wellness
EP3463617A4 (en) METHOD FOR DETERMINING THE CAPACITY USED TO USE AN AIR FILTER
EP3113684A4 (en) Method and system for assessing motion symptoms
EP3512539A4 (en) METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
IL257146A (en) A method for reducing host cell proteins in affinity chromatography
EP3234698A4 (en) Positional control features between replaceable units of an electrophotographic image forming device
PL3358355T3 (pl) Zastosowanie surowiczych peroksyredoksyn dwucysteinowych (2-Cys-PRDX) jako biomarkerów przewlekłej choroby nerek (PChN, ang. CKD) takiej jak toczniowe zapalenie nerek (LN), nefropatia IgA (IgAN) i autosomalna dominująca wielotorbielowatość nerek (ADPKD) użytecznych do diagnozowania tych chorób i sposoby różnicowania tych chorób
EP3538893A4 (en) PROCESSES FOR IDENTIFYING CANDIDATE BIOMARKERS
EP3528824A4 (en) METHOD FOR PREDICTING THE TRANSPLANT-HOST REACTION
EP3204516A4 (en) Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
EP3191629A4 (en) Peptide microarrays and novel biomarkers for celiac disease
PL3152330T3 (pl) SPOSOBY DIAGNOZOWANIA PRZEWLEKŁEJ OBTURACYJNEJ CHOROBY PŁUC (POChP) Z ZASTOSOWANIEM NOWYCH BIOMARKERÓW MOLEKULARNYCH
EP3535584A4 (en) IMMUNOASSAY SYSTEM FOR RECOMMENDING TESTS BASED ON INPUT DATA
EP3258927B8 (en) Host defense protein (hdp) mimetics for prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract
PL3235666T3 (pl) Miech na przejściu pomiędzy dwoma pojazdami połączonymi przegubowo
EP3807077A4 (en) Evaluating candidate virtual build volumes
EP3695224A4 (en) Prognosis and progression biomarkers for chronic kidney disease
EP3112867A4 (en) Qualitative predictive method for differential diagnosis of pneumococcic, meningococcic and viral menigitis, differential meningitis diagnostic method and kit
EP3894581A4 (en) NUCLEIC ACID BIOMARKERS FOR PLACENTAL DYSFUNCTION
EP3400441A4 (en) SIGNATURES OF BIOMARKERS FOR THE DIFFERENTIATION OF LYME DISEASE AND METHODS OF USE THEREOF
PL3337817T3 (pl) Sposób zmniejszania zawartości białek komórek gospodarza w chromatografii powinowactwa
HK1250176A1 (zh) 用於确定细胞疗法的临床反应的生物标志物
EP3323828A4 (en) ANTIBODIES FOR DETERMINING THE SEX OF SPERMA AND USE THEREOF